Listen to the audio version of this article (generated by artificial intelligence).
Hello reader.
If your family includes Millennials and Generation Z, you’ve probably heard one word thrown around a lot: “hype.” They use it to talk about something exciting, active, or highly anticipated.
But between the 1910s and 1920s, long before it entered the lexicon of youthful enthusiasm, The noise It refers to a scam that a fraudster may use to deceive or overcharge customers.
By 1967, the meaning had evolved to refer to “excessive or misleading advertising or advertising.”
All of these previous definitions represent forms of deception, which is exactly how hype works in the stock market. It tempts investors to “chase stocks” that are already very popular.
For short periods of time, chasing the hype can lead to huge gains. But holding on to these gains is not easy. Once the hype ends, stocks usually decline quickly. During the last three years of the dot-com boom, for example, Cisco Systems Inc. (cisco) It rose more than 1300%! But only one year after At that peak, the stock collapsed by more than 80%…and only regained its peak price afterwards this A year, after 26 years.
Today, AI is without a doubt the most “noisy” topic in the stock market… which is why investors are climbing over each other to throw money at “AI darlings.” Even Cisco is on that list again!
Many investors have abandoned sectors they once owned to chase the AI gold rush, leaving behind a particularly ‘unwanted’ sector:
health care.
per day Smart moneyI will explain how the hype surrounding AI trading distracts from potentially profitable pharmaceutical stocks.
And why this disconnect, along with many promising developments, could make now a good time to take another look at the sector.
Let’s dive in…
How has AI commerce left healthcare behind?
Popular ways to profit from the rise of artificial intelligence include investing in its infrastructure, data centers, and the energy and semiconductors needed to power it.
Nvidia company (NVDA)the most popular chip company, has jumped 1,255% since November 30, 2022, when ChatGPT debuted and forever changed the way we use technology and artificial intelligence…
Vertif Holding Company (VRT)which provides computing services and cooling solutions for data centers, has risen 2,579% since then…
Lumentum Holding Company (Light)which provides optical solutions for data centers, jumped 1,658%.
All while iShares Pharmaceuticals Corporation (IHE) It grew by just 43% over the same period. Compared to artificial intelligence and huge cover Technology stocksThis doesn’t seem like an exaggeration.
Pharmaceutical stocks have not shared the same speculative excitement as their AI counterparts. The NYSE Arca Drug Index trades for just 16 times forward earnings, barely half the Nasdaq Composite’s valuation of 29 times.
Healthcare has historically commanded a premium or near-market rating, driven by steady demand, steady cash flows, aging demographics, and resilience during recessions.
but, Baron I noticed last summer that these stocks were trading at some of their cheapest relative valuations versus the broader market in nearly 30 years.
And they still are today… because investors were selling them to buy AI-related stocks instead.
but Health care stocksEarnings remained quite flat, while valuation multiples saw significant pressure. As a result, they did not perform well, although profits remained strong.
This change has resulted in healthcare stocks trading at a discount – making them more attractive given their growth potential.
but, where Investment in this sector is still important…
Where AI actually helps healthcare
It is important to note that cheap valuations do not automatically lead to good investments.
There are several other reasons why pharmaceutical stocks are trading at depressed levels right now, including ongoing uncertainty around government policy and healthcare regulation.
The current environment at the Department of Health and Human Services, coupled with broader debates over vaccine policy, drug pricing, and Medicare reform, has made investors cautious.
But at the same time, AI has helped create strong new growth for select companies in healthcare – especially those using AI to accelerate and improve the drug discovery process.
An article from the World Economic Forum published earlier this year explains how AI is transforming three key stages in drug discovery:
- Identifying disease targets (changing how biopharmaceuticals identify the biological drivers of disease),
- Compound generation (leveraging generative AI to create more molecules),
- and safety forecasting (by organizing and analyzing historical data).
The pharmaceutical industry has officially entered the era of artificial intelligence, and no major pharmaceutical company wants to be left behind. Collectively, he recognizes the potential of AI to revolutionize the drug discovery process.
This is especially true as Amnesty International agent Further transformation in healthcare.
Just this week, Owkin, an AI company that develops AI tools for drug discovery and pharmaceutical research, said it is expanding its partnership with the pharmaceutical giant AstraZeneca plc (AZN) To build specialized AI agents for AstraZeneca’s research teams.
The trend toward semi-autonomous AI agents managing parts of the pharmaceutical workflow is still in its early stages, but I expect this trend to grow significantly.
This transformative technology could improve the plight of humanity and Enriching forward-looking investors.
But betting on a make-or-break biotech company driven by unchecked AI hype may not be the best way to profit from…
The risk-reward play is worth watching now
Alternatively, at this stage of the opportunity, large-cap pharmaceutical companies may offer better risk-reward profiles.
I want investors to focus not just on growth, but on profitable companies that have more defensive characteristics – especially as the hype around agentic AI grows.
That’s why I have my eye on a particular pharmaceutical business.
You can find information about this healthcare play inside my profile Three expedited transactions for the agent’s account report, outlining a total of three deals designed to accelerate gains from companies that successfully leverage agentic AI.
Learn how to access this report by clicking here.
You will be taken to Important offer I explain some of the best ways to navigate the current AI landscape, especially as agentic AI gains prominence and the excitement surrounding it clouds investors’ judgment.
During my presentation, I also compromise My #1 stock pick for free – A company applying AI broadly across a wide range of industries, including automation and service businesses – and even healthcare.
Click here for all the information.
It is considered,
Eric Fry
